Science Translational Medicine | Enhanced SARS-CoV-2-Specific T Cell Responses in Individuals with B Cell Deficiency Reduce the Risk of Severe COVID-19

The study found that patients with B cell deficiency exhibit significantly enhanced CD8+ T cell responses following SARS-CoV-2 infection or vaccination. Even in the absence of antibodies, T cell immunity reduces the risk of severe disease, revealing the protective role of T cells when antibody responses are lacking.

 

Literature Overview

This article, 'T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19,' published in the journal Science Translational Medicine, reviews and summarizes the characteristics of T cell immune responses to natural SARS-CoV-2 infection and mRNA vaccination in individuals with B cell deficiency, as well as their impact on clinical outcomes. The study found that although these patients struggle to generate anti-spike protein antibodies, their CD8+ T cell responses are significantly enhanced, and vaccination substantially reduces the risk of severe disease or death. Through multidimensional immune phenotyping and clinical data correlation, this research systematically reveals the compensatory enhancement mechanism and protective value of T cell immunity in the absence of humoral immunity.

Background Knowledge

During SARS-CoV-2 infection and vaccination, neutralizing antibodies are typically considered key to preventing severe disease. However, individuals with B cell deficiency—such as those receiving the anti-CD20 monoclonal antibody rituximab or patients with common variable immunodeficiency (CVID)—are unable to produce effective antibodies and thus face higher risks of severe illness and death. The immune protection mechanisms in these populations remain unclear, and whether T cell immunity alone can provide protection in the absence of antibody responses is still debated. Previous studies have shown that CD8+ T cells can recognize and eliminate virus-infected cells, and the strength of this response correlates with milder disease outcomes. However, whether B cell depletion affects T cell function, and whether compensatory enhancement occurs, has not been systematically studied. Moreover, rituximab treatment may affect T cell memory differentiation by depleting CD20^dim T cell subsets, thereby altering the landscape of antiviral immune responses. This study focuses on individuals with B cell deficiency, aiming to elucidate the relationship between T cell responses and clinical protection, filling a critical gap in our understanding of vaccine-mediated protection in immunocompromised individuals and providing a theoretical basis for optimizing immunization strategies in this population.

 

 

Research Methods and Experiments

The study enrolled 89 participants, divided into a non-RTX group (n=44), an RTX-treated group (n=33), and a CVID group (n=12), with immune phenotyping analyzed by flow cytometry. SARS-CoV-2-specific CD4+ and CD8+ T cell responses to spike protein and antigens such as ORF3A were assessed using IFN-γ ELISpot and CFSE proliferation assays. Longitudinal analysis was performed on samples collected before and after mRNA vaccination to evaluate memory T cell differentiation. Additionally, retrospective analysis of clinical outcomes was conducted in 110 RTX-treated patients infected with SARS-CoV-2, with multivariable logistic regression used to assess vaccine effectiveness in relation to anti-spike antibody levels. Further analyses included characterization of T cell memory subsets via CD45RA and CD62L staining, and measurement of CD8+CD20^dim T cell frequency changes. Preexisting immunity was also evaluated by assessing T cell responses to CMV, EBV, and influenza virus (CEF).

Key Conclusions and Perspectives

• Individuals with B cell deficiency—either due to rituximab (RTX) treatment or CVID—exhibit significantly stronger spike protein-specific CD8+ T cell effector and proliferative responses after SARS-CoV-2 infection or mRNA vaccination compared to healthy controls, particularly evident in the CD8+ T cell compartment
• Despite lacking anti-spike protein antibodies, RTX-treated patients who received vaccination still experienced approximately a 4.8-fold reduction in the risk of moderate-to-critical or severe COVID-19, indicating that T cell immunity can independently mediate protection
• RTX treatment increases the frequency of naïve T cells while reducing memory effector T cells in the CD8+ subset, partly due to depletion of CD20^dim effector memory T cells (CD8+CD20^dim TEMRA)
• The frequency of naïve CD8+ T cells positively correlates with the proliferative capacity of spike-specific CD8+ T cells post-vaccination, suggesting that an expanded naïve T cell pool may promote stronger de novo T cell responses
• Although SARS-CoV-2-specific T cell responses are enhanced, RTX treatment weakens preexisting T cell immunity to CMV, EBV, and influenza, likely due to depletion of CD8+CD20^dim T cells
• Vaccination restores T cell proliferative capacity to CEF antigens in some RTX-treated patients, suggesting that mRNA vaccines may enhance nonspecific T cell memory function

Research Significance and Prospects

This study challenges the traditional view that 'antibodies are the sole mediators of protective immunity,' demonstrating that in individuals with B cell deficiency, T cell immunity can be compensatorily enhanced and provide significant clinical protection. It provides strong evidence for vaccination strategies in high-risk populations, emphasizing that even in the absence of detectable antibodies, T cell responses may still confer defense. The study also reveals a dual effect of RTX treatment on T cell subsets: on one hand, it expands the naïve T cell pool to promote de novo immune responses; on the other, it impairs preexisting antiviral memory, suggesting that timing of treatment relative to vaccination may be crucial.

Future research should further explore how to optimize vaccination timing to maximize T cell responses—such as administering booster doses during early B cell recovery. Additionally, developing vaccine strategies specifically targeting CD8+ T cells may offer more durable protection for immunocompromised individuals. These findings also provide new insights for infection prevention in other antibody-deficient conditions, advancing the development of personalized immune intervention strategies.

 

 

Conclusion

This study systematically reveals the remodeling characteristics of T cell immunity in individuals with B cell deficiency following SARS-CoV-2 infection and vaccination. Although these patients struggle to generate neutralizing antibodies, their CD8+ T cell responses are significantly enhanced, and vaccination substantially reduces the risk of severe disease, demonstrating that T cell immunity can independently provide protection in the absence of humoral immunity. Mechanistically, rituximab treatment increases the frequency of naïve CD8+ T cells, potentially promoting stronger de novo T cell responses by expanding the naïve T cell pool. At the same time, the treatment depletes CD20-expressing effector memory T cells, weakening preexisting immunity to other viruses, indicating complex immune regulation. These findings underscore the critical role of T cells in anti-SARS-CoV-2 immunity, especially when antibody responses are limited. The results support vaccination in B cell–deficient populations and suggest that monitoring T cell responses may be more clinically informative than antibody testing. Furthermore, this work provides a theoretical foundation for developing T cell–focused vaccine strategies, potentially improving infection protection for immunocompromised patients.

 

Reza Zonozi, Lucy C Walters, Aaron Shulkin, John L Niles, and Gaurav D Gaiha. T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19. Science translational medicine.